SURROZEN INC (SRZN) Stock Price, Quote, News and Overview
NASDAQ:SRZN - Nasdaq - US86889P2083 - Common Stock - Currency: USD
SRZN Quote, Performance and Key Statistics
NASDAQ:SRZN (2/21/2025, 8:00:00 PM)
11.2
-0.35 (-3.03%)
The current stock price of SRZN is 11.2 USD. In the past month the price decreased by -2.78%. In the past year, price decreased by -10.18%.
SRZN Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 19.97 | 357.10B | ||
| AMGN | AMGEN INC | 15.29 | 162.72B | ||
| GILD | GILEAD SCIENCES INC | 23.85 | 137.00B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 1669.79 | 124.40B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.34 | 76.56B | ||
| ARGX | ARGENX SE - ADR | N/A | 39.16B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 32.32B | ||
| BNTX | BIONTECH SE-ADR | N/A | 28.77B | ||
| ONC | BEIGENE LTD-ADR | N/A | 27.25B | ||
| NTRA | NATERA INC | N/A | 21.43B | ||
| BIIB | BIOGEN INC | 8.54 | 20.49B | ||
| SMMT | SUMMIT THERAPEUTICS INC | N/A | 16.31B |
Related stock screener links
About SRZN
Company Profile
Surrozen, Inc. is a clinical stage biotechnology company. The company is headquartered in South San Francisco, California and currently employs 42 full-time employees. The company went IPO on 2020-11-23. The firm is engaged in discovering and developing drug candidates to selectively modulate the Wnt pathway, a critical mediator of tissue repair, in a range of organs and tissues. The firm is developing tissue-specific antibodies designed to engage the body’s existing biological repair mechanisms with a current focus on severe liver and eye diseases. Its two lead product candidates include SZN-043 and SZN-413. SZN-043 is the first development candidate using Surrozen’s SWEETS technology. The company is developing SZN-043 for severe liver diseases, initially focusing on alcohol-associated hepatitis. The company has completed Phase I a clinical trial in patients with chronic liver disease and healthy volunteers. SZN-413 is a bi-specific antibody targeting Fzd4-mediated Wnt signaling designed using Surrozen’s SWAP technology. SZN-413 is being developed for the treatment of retinal vascular-associated diseases.
Company Info
SURROZEN INC
171 Oyster Point Blvd, Suite 400
South San Francisco CALIFORNIA US
CEO: Gad Soffer
Employees: 42
Company Website: https://www.surrozen.com
Investor Relations: https://investors.surrozen.com/
Phone: 16504752820
SURROZEN INC / SRZN FAQ
What is the stock price of SURROZEN INC today?
The current stock price of SRZN is 11.2 USD. The price decreased by -3.03% in the last trading session.
What is the ticker symbol for SURROZEN INC stock?
The exchange symbol of SURROZEN INC is SRZN and it is listed on the Nasdaq exchange.
On which exchange is SRZN stock listed?
SRZN stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for SURROZEN INC stock?
8 analysts have analysed SRZN and the average price target is 32.64 USD. This implies a price increase of 191.43% is expected in the next year compared to the current price of 11.2. Check the SURROZEN INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is SURROZEN INC worth?
SURROZEN INC (SRZN) has a market capitalization of 36.40M USD. This makes SRZN a Nano Cap stock.
How many employees does SURROZEN INC have?
SURROZEN INC (SRZN) currently has 42 employees.
What are the support and resistance levels for SURROZEN INC (SRZN) stock?
SURROZEN INC (SRZN) has a support level at 10.4 and a resistance level at 11.43. Check the full technical report for a detailed analysis of SRZN support and resistance levels.
Should I buy SURROZEN INC (SRZN) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of SRZN, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of SRZN, evaluating the profitability, health, valuation and growth aspects
- SURROZEN INC (SRZN) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- SURROZEN INC (SRZN) Sales and EPS estimates to see what analysts future expectations are.
- SURROZEN INC (SRZN) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- SURROZEN INC (SRZN) Insider and Institutional Ownership to learn about the owners and their transactions.
- SURROZEN INC (SRZN) Stock Chart to make your own analysis
- SURROZEN INC (SRZN) Latest news and press-releases to stay up to date.
Does SURROZEN INC (SRZN) stock pay dividends?
SRZN does not pay a dividend.
What is the Price/Earnings (PE) ratio of SURROZEN INC (SRZN)?
SURROZEN INC (SRZN) does not have a PE ratio as the earnings reported over the last twelve months were negative (-10.63).
What is the Short Interest ratio of SURROZEN INC (SRZN) stock?
The outstanding short interest for SURROZEN INC (SRZN) is 4.36% of its float. Check the ownership tab for more information on the SRZN short interest.
SRZN Technical Analysis
ChartMill assigns a technical rating of 4 / 10 to SRZN. When comparing the yearly performance of all stocks, SRZN turns out to be only a medium performer in the overall market: it outperformed 66.9% of all stocks.
SRZN Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to SRZN. No worries on liquidiy or solvency for SRZN as it has an excellent financial health rating, but there are worries on the profitability.
SRZN Financial Highlights
Over the last trailing twelve months SRZN reported a non-GAAP Earnings per Share(EPS) of -10.63. The EPS increased by 38.91% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -92.58% | ||
| ROE | -784.15% | ||
| Debt/Equity | 0 |
SRZN Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 80% to SRZN. The Buy consensus is the average rating of analysts ratings from 8 analysts.